Multiple myeloma (MM) is the second most common hematologic malignancy. Despite the more effective therapies were introduced, this incurable disease remains highly heterogeneous in clinical outcome. Accurate predicative markers for prognosis are needed to develop appropriate treatment in newly diagnosed MM.
This abstract and the presentation materials are available to members only; a login is required.